0000937556-17-000177.txt : 20170713 0000937556-17-000177.hdr.sgml : 20170713 20170713163248 ACCESSION NUMBER: 0000937556-17-000177 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170713 FILED AS OF DATE: 20170713 DATE AS OF CHANGE: 20170713 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MASIMO CORP CENTRAL INDEX KEY: 0000937556 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 330368882 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 52 DISCOVERY CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-297-7000 MAIL ADDRESS: STREET 1: 52 DISCOVERY CITY: IRVINE STATE: CA ZIP: 92618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FITCH SANFORD CENTRAL INDEX KEY: 0001198927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33642 FILM NUMBER: 17963871 MAIL ADDRESS: STREET 1: 1212 TERRA BELLA AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 4 1 wf-form4_149997795355644.xml FORM 4 X0306 4 2017-07-13 0 0000937556 MASIMO CORP MASI 0001198927 FITCH SANFORD C/O MASIMO CORPORATION 52 DISCOVERY IRVINE CA 92618 1 0 0 0 Common Stock 2017-07-13 4 M 0 6000 20.19 A 89249 D Common Stock 2017-07-13 4 S 0 6000 91.8921 D 83249 D Non-Qualified Stock Option (Right to Buy) 20.19 2017-07-13 4 M 0 6000 0 D 2012-10-27 2021-10-27 Common Stock 6000.0 0 D The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of June 6, 2017, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 represents the weighted average sale price per share. The actual sale prices ranged from a low of $91.18 per share to a high of $92.60 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This option was granted on October 27, 2011 and is exercisable as it vested. This option vests over a five year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date. /s/ David J. Van Ramshorst, Attorney-In-Fact 2017-07-13